The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Zeng, Taofei; Cao, Yuqing; Jin, Tianqiang; Tian, Yu; Dai, Chaoliu; Xu, Feng

doi:10.1186/s13046-021-02053-y

Cited by 33 publications

(17 citation statements)

References 84 publications

(152 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that the combined CD112R and TIGIT blockade allowed diffusion of CD4+ T cells and increased the productions of cytokines such as IFN-γ, IL-2, IL-5, IL-10, and IL-13. Moreover, blockade to these two checkpoints led to restored cytotoxicity and expansion of CD8+ T cells [75].…”

Section: Tigit Signaling Pathwaysmentioning

confidence: 99%

Immune Checkpoints: The Rising Branch in Cancer Immunotherapy

Nurlaila¹

2023

Immune Checkpoint Inhibitors - New Insights and Recent Progress

View full text Add to dashboard Cite

In the cancer therapy realm, concepts of immunotherapy rose as a response to emerging adverse effects caused by conventional therapies, which to some cases even more quality-of-life-reducing than the cancer itself. Immunotherapy is aimed to systematically enhance immunity to eradicate cancerous cells without harming healthy neighbor cells. In this platform, immune checkpoint molecules are under massive explorations and have been thought to be bringing excellent outlook clinically. These molecules hinder anticancer immunity. As a result, cancer growth is favored. Therefore, inactivation of immune checkpoint by blocking engagement of checkpoint receptors and their cognate ligands will restore the anticancer functions of immune system elements; hence, they can reclaim their power to eradicate cancers. Each checkpoint possesses specific downstream mechanism for which the inhibitors are formulated. In this chapter, we discuss four major checkpoints in the context of general characteristics, structures, and their roles in some cancers. Relevant recent progress in respective checkpoint molecules is also discussed to broaden our horizon on how cancers and immune checkpoint molecules are at interplay.

show abstract

Section: Tigit Signaling Pathwaysmentioning

confidence: 99%

Immune Checkpoints: The Rising Branch in Cancer Immunotherapy

Nurlaila¹

2023

Immune Checkpoint Inhibitors - New Insights and Recent Progress

View full text Add to dashboard Cite

show abstract

“…TIGIT (T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain) [ 357 ] is expressed by T cell populations [ 358 ] and NK cells [ 359 ] and binds both CD112 [ 360 ], which is expressed by DCs [ 361 ] and various non-immune cell types [ 362 , 363 ], and CD155 [ 358 ]. By using solubilized TIGIT, engagement of CD155 was demonstrated to result in Treg activation [ 364 ] and inhibition of DCs [ 358 ] and NK cells [ 359 ].…”

Section: Emerging Immune Checkpoints and Their Impact On Non-t-cell I...mentioning

confidence: 99%

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

Kuske

Haist

Jung

et al. 2022

Cancers

View full text Add to dashboard Cite

The approval of immune checkpoint inhibitors (ICI) that serve to enhance effector T-cell anti-tumor responses has strongly improved success rates in the treatment of metastatic melanoma and other tumor types. The currently approved ICI constitute monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein (CTLA)-4 and anti-programmed cell death (PD)-1. By this, the T-cell-inhibitory CTLA-4/CD80/86 and PD-1/PD-1L/2L signaling axes are inhibited. This leads to sustained effector T-cell activity and circumvents the immune evasion of tumor cells, which frequently upregulate PD-L1 expression and modulate immune checkpoint molecule expression on leukocytes. As a result, profound clinical responses are observed in 40–60% of metastatic melanoma patients. Despite the pivotal role of T effector cells for triggering anti-tumor immunity, mounting evidence indicates that ICI efficacy may also be attributable to other cell types than T effector cells. In particular, emerging research has shown that ICI also impacts innate immune cells, such as myeloid cells, natural killer cells and innate lymphoid cells, which may amplify tumoricidal functions beyond triggering T effector cells, and thus improves clinical efficacy. Effects of ICI on non-T cells may additionally explain, in part, the character and extent of adverse effects associated with treatment. Deeper knowledge of these effects is required to further develop ICI treatment in terms of responsiveness of patients to treatment, to overcome resistance to ICI and to alleviate adverse effects. In this review we give an overview into the currently known immunomodulatory effects of ICI treatment in immune cell types other than the T cell compartment.

show abstract

“…Further NK cell co-inhibitory immune checkpoints also expressed by other immune cell types that are currently in the focus of interest are T cell immunoglobulin and mucin domain molecule 3 (Tim-3) [ 95 ], T cell immune receptor with immunoglobulin and ITIM domains (TIGIT) [ 96 ], and CD112 receptor (CD112R) [ 97 ]. Whereas Tim-3 recognizes galectin-9, HMGB1 and CEACAM1, the latter two are specific for the nectin family molecules CD112, CD113, and CD155 [ 98 ], as well as for the recently detected nectin-4 in the case of TIGIT only [ 96 ].…”

Section: Harnessing Of Autologous Nk Cellsmentioning

confidence: 99%

“…Regarding CD112R, it is a molecule considered as having a high potential in cancer immunotherapy and it has already been shown that its ligand CD112 has a diagnostic and prognostic value in several cancers of the digestive tract and others [ 97 ].…”

Section: Harnessing Of Autologous Nk Cellsmentioning

confidence: 99%

A Hot Topic: Cancer Immunotherapy and Natural Killer Cells

Michel

Ollert

Zimmer

2022

IJMS

View full text Add to dashboard Cite

Despite significant progress in recent years, the therapeutic approach of the multiple different forms of human cancer often remains a challenge. Besides the well-established cancer surgery, radiotherapy and chemotherapy, immunotherapeutic strategies gain more and more attention, and some of them have already been successfully introduced into the clinic. Among these, immunotherapy based on natural killer (NK) cells is considered as one of the most promising options. In the present review, we will expose the different possibilities NK cells offer in this context, compare data about the theoretical background and mechanism(s) of action, report some results of clinical trials and identify several very recent trends. The pharmaceutical industry is quite interested in NK cell immunotherapy, which will benefit the speed of progress in the field.

show abstract

The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Cited by 33 publications

References 84 publications

Immune Checkpoints: The Rising Branch in Cancer Immunotherapy

Immune Checkpoints: The Rising Branch in Cancer Immunotherapy

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

A Hot Topic: Cancer Immunotherapy and Natural Killer Cells

Contact Info

Product

Resources

About